Erratum: Metabolic Activity Measured on PET/CT Correlates with Clinical Outcomes in Patients with Limb and Girdle Sarcomas (Journal of Surgical Oncology (2014) 109 (410-414) doi: 10.1002/jso.23523);Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas

Journal of Surgical Oncology

Volumn 109, Issue 5, 2014, Pages 410-414

  Skamene, Sonia R ^a   Rakheja, Rajan ^b   Dalhstrom, Kristina R ^c   Roberge, David ^d   Nahal, Ayoub ^a   Charest, Mathieu ^b   Turcotte, Robert ^a   Hickeson, Marc ^b   Freeman, Carolyn ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

Author keywords

FDG PET; prognosis; sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARTILAGE TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEATH; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; TREATMENT DURATION;

FDG-PET; PROGNOSIS; SARCOMA; SUVMAX;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84897027975     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23828     Document Type: Erratum

References (22)

1. Howlader N, Noone AM, Krapcho M, et al.: (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2010/ based on November 2012 SEER data submission, posted to the SEER web cite, April 2013.
2. Trojani M, Contesso G, Coindre JM, et al.: Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
3. Clark MA, Fisher C, Judson I, et al.: Soft-tissue sarcomas in adults. N Engl J Med 2005; 353: 701-711.
4. Karam I, Devic S, Hickeson M, et al.: PET/CT for radiotherapy treatment planning in patients with soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2009; 75: 817-821.
5. Hatt M, Cheze le Rest C, Descourt P, et al.: Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys 2010; 77: 301-308.
6. Roberge D, Vakilian S, Alabed YZ, et al.: FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma 2012; 2012: 960194.
7. Roberge D, Hickeson M, Charest M, et al.: Initial McGill experience with fluorodeoxyglucose PET/CT staging of soft-tissue sarcoma. Curr Oncol 2010; 17: 18-22.
8. Eary JF, O'Sullivan F, Powitan Y, et al.: Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 2002; 29: 1149-1154.
9. Folpe AL, Lyles RH, Sprouse JT, et al.: (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6: 1279-1287.
10. Fletcher CDM, Unni KK, Mertens F, editors: World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon, France: International Agency for Research on Cancer; 2002.
11. Rubin BP, Fletcher CD, Inwards C, et al.: Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med 2006; 130: 1616-1629.
12. Ahuja V, Coleman RE, Herndon J, et al.: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-924.
13. Higashi K, Ueda Y, Arisaka Y, et al.: 18-F-FDG uptake as a biological prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43: 39-45.
14. max in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009; 4: 875-879.
15. La TH, Filion EJ, Turnbull BB, et al.: Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1335-1341.
16. Kidd EA, Dehdashti F, Siegel BA, et al.: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol 2010; 95: 288-291.
17. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, et al.: Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005; 241: 286-294.
18. 18 F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23: 8828-8834.
19. Hawkins DS, Conrad EU III, Butrynski JE:, [F-18]-fluorodeoxy- d -glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009; 115: 3519-3525.
20. 18 F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 2009; 50: 340-347.
21. Vallieres M, Freeman CR, Skamene S, et al.: FDG-PET features and outcomes in patients with soft-tissue sarcomas of the extremities [Abstract]. Int J Radiat Oncol Biol Phys 2012; 84: S167-S168.
22. Vallieres M, Freeman CR, Skamene S, et al.: Prediction of tumour outcomes using joint FDG-PET/MR diagnostic imaging features [Abstract]. Radiother Oncol 2013; 108: S548.